Botulinum toxin type a injections for cervical and shoulder girdle myofascial pain using an enriched protocol design

Anesthesia and Analgesia

Volumn 118, Issue 6, 2014, Pages 1326-1335

  Nicol, Andrea L ^a   Wu, Irene I ^a   Ferrante, F Michael ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; IBUPROFEN; PLACEBO; TRAMADOL;

ADULT; ARTHRALGIA; ARTICLE; BRIEF PAIN INVENTORY; CERVICAL MYOFASCIAL PAIN; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HUMAN; LEVATOR SCAPULAE MUSCLE; MAJOR CLINICAL STUDY; MALE; MYOFASCIAL PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEMISPINALIS CAPITIS; SHOULDER GIRDLE MYOFASCIAL PAIN; SKELETAL MUSCLE; SLEEP; SPLENIUS CAPITIS; TRAPEZIUS MUSCLE;

ADOLESCENT; ADULT; AGED; BOTULINUM TOXINS, TYPE A; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MYOFASCIAL PAIN SYNDROMES; NECK PAIN; NEUROMUSCULAR AGENTS; PAIN MEASUREMENT; QUALITY OF LIFE; SHOULDER PAIN; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901314133     PISSN: 00032999     EISSN: 15267598     Source Type: Journal    
DOI: 10.1213/ANE.0000000000000192     Document Type: Article

References (42)

1. Borg-Stein J, Simons DG. Focused review: Myofascial pain. Arch Phys Med Rehabil 2002;83:S40-7, S48-9
2. Simons DG, Travell JG, Simons, LS. Myofascial Pain and Dysfunction: The Trigger Point Manual. Upper Half of Body. Vol 1. 2nd ed. Baltimore: Williams & Wilkins, 1999
3. Cummings M, Baldry P. Regional myofascial pain: Diagnosis and management. Best Pract Res Clin Rheumatol 2007;21:367-87 (Pubitemid 46804372)
4. Simons DG. Review of enigmatic MTrPs as a common cause of enigmatic musculoskeletal pain and dysfunction. J Electromyogr Kinesiol 2004;14:95-107 (Pubitemid 38169110)
5. Shah JP, Danoff JV, Desai MJ, Parikh S, Nakamura LY, Phillips TM, Gerber LH. Biochemicals associated with pain and inflammation are elevated in sites near to and remote from active myofascial trigger points. Arch Phys Med Rehabil 2008;89:16-23 (Pubitemid 350299018)
6. Mense S. Muscle pain: Mechanisms and clinical significance. Dtsch Arztebl Int 2008;105:214-9 (Pubitemid 351487273)
7. Watkins LR, Hutchinson MR, Ledeboer A, Wieseler-Frank J, Milligan ED, Maier SF. Norman Cousins Lecture. Glia as the " bad guys": Implications for improving clinical pain control and the clinical utility of opioids. Brain Behav Immun 2007;21:131-46
8. Climent JM, Kuan TS, Fenollosa P, Martin-Del-Rosario F. Botulinum toxin for the treatment of myofascial pain syndromes involving the neck and back: A review from a clinical perspective. Evid Based Complement Alternat Med 2013;2013:381459
9. Ferrante FM, Bearn L, Rothrock R, King L. Evidence against trigger point injection technique for the treatment of cervicothoracic myofascial pain with botulinum toxin type A. Anesthesiology 2005;103:377-83 (Pubitemid 41076735)
10. Aker PD, Gross AR, Goldsmith CH, Peloso P. Conservative management of mechanical neck pain: Systematic overview and meta-Analysis. BMJ 1996;313:1291-6 (Pubitemid 26394933)
11. Gross AR, Aker PD, Goldsmith CH, Peloso P. Physical medicine modalities for mechanical neck disorders. Cochrane Database Syst Rev 2000;2:CD000961
12. Hoving JL, Gross AR, Gasner D, Kay T, Kennedy C, Hondras MA, Haines T, Bouter LM. A critical appraisal of review articles on the effectiveness of conservative treatment for neck pain. Spine (Phila Pa 1976) 2001;26:196-205
13. Lang AM. A pilot study of botulinum toxin type A (Botox), administered using a novel injection technique, for the treatment of myofascial pain. Am J Pain Manage 2000;10:108-12 (Pubitemid 33362187)
14. Wheeler AH, Goolkasian P, Gretz SS. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine (Phila Pa 1976) 1998;23:1662-6
15. Borodic GE, Acquadro M, Johnson EA. Botulinum toxin therapy for pain and inflammatory disorders: Mechanisms and therapeutic effects. Expert Opin Investig Drugs 2001;10:1531-44 (Pubitemid 32717333)
16. Hou CR, Tsai LC, Cheng KF, Chung KC, Hong CZ. Immediate effects of various physical therapeutic modalities on cervical myofascial pain and trigger-point sensitivity. Arch Phys Med Rehabil 2002;83:1406-14
17. Jankovik J, Albanese A, Atassi MZ, Dolly JO, Hallett M, Mayer NH. Botulinum Toxin: Therapeutic Clinical Practice and Science. New York, NY: Saunders, 2009
18. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004;107:125-33 (Pubitemid 38058707)
19. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005;26:785-93 (Pubitemid 41427518)
20. Jabbari B. Botulinum neurotoxins in the treatment of refractory pain. Nat Clin Pract Neurol 2008;4:676-85
21. Jabbari B, Machado D. Treatment of refractory pain with botulinum toxins-An evidence-based review. Pain Med 2011;12:1594-606
22. Katz N. Enriched enrollment randomized withdrawal trial designs of analgesics: Focus on methodology. Clin J Pain 2009;25:797-807
23. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58 (Pubitemid 33016608)
24. Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain 2004;5:133-7 (Pubitemid 38850184)
25. Griegel-Morris P, Larson K, Mueller-Klaus K, Oatis CA. Incidence of common postural abnormalities in the cervical, shoulder, and thoracic regions and their association with pain in two age groups of healthy subjects. Phys Ther 1992;72:425-31
26. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83
27. En MC, Clair DA, Edmondston SJ. Validity of the Neck Disability Index and Neck Pain and Disability Scale for measuring disability associated with chronic, non-Traumatic neck pain. Man Ther 2009;14:433-8
28. McQuay HJ, Derry S, Moore RA, Poulain P, Legout V. Enriched enrolment with randomised withdrawal (EERW): Time for a new look at clinical trial design in chronic pain. Pain 2008;135:217-20
29. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: A literature review. Arch Intern Med 2003;163:2433-45 (Pubitemid 37385786)
30. Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories-IA and-II in psychiatric outpatients. J Pers Assess 1996;67:588-97 (Pubitemid 26382973)
31. Coté TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: Adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 2005;53:407-15 (Pubitemid 41195960)
32. Bhatia KP, Münchau A, Thompson PD, Houser M, Chauhan VS, Hutchinson M, Shapira AH, Marsden CD. Generalised muscular weakness after botulinum toxin injections for dystonia: A report of three cases. J Neurol Neurosurg Psychiatry 1999;67:90-3 (Pubitemid 29278334)
33. Sheean GL, Murray NM, Marsden CD. Pain and remote weakness in limbs injected with botulinum toxin A for writer's cramp. Lancet 1995;346:154-6
34. Shaari CM, George E, Wu BL, Biller HF, Sanders I. Quantifying the spread of botulinum toxin through muscle fascia. Laryngoscope 1991;101:960-4
35. Freund BJ, Schwartz M. Treatment of whiplash associated neck pain [corrected] with botulinum toxin-A: A pilot study. J Rheumatol 2000;27:481-4 (Pubitemid 30095484)
36. Göbel H, Heinze A, Reichel G, Hefter H, Benecke R; Dysport myofascial pain study group. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: Results from a randomized double-blind placebo-controlled multicentre study. Pain 2006;125:82-8
37. Benecke R, Heinze A, Reichel G, Hefter H, Göbel H; Dysport Myofascial Pain Study Group. Botulinum type A toxin complex for the relief of upper back myofascial pain syndrome: How do fixed-location injections compare with trigger point-focused injections?. Pain Med 2011;12:1607-14
38. Miller D, Richardson D, Eisa M, Bajwa RJ, Jabbari B. Botulinum neurotoxin-A for treatment of refractory neck pain: A randomized, double-blind study. Pain Med 2009;10:1012-7
39. Wheeler AH, Goolkasian P, Gretz SS. Botulinum toxin A for the treatment of chronic neck pain. Pain 2001;94:255-60 (Pubitemid 33145395)
40. Ojala T, Arokoski JP, Partanen J. The effect of small doses of botulinum toxin a on neck-shoulder myofascial pain syndrome: A double-blind, randomized, and controlled crossover trial. Clin J Pain 2006;22:90-6 (Pubitemid 44378566)
41. Graboski CL, Gray DS, Burnham RS. Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: A randomised double blind crossover study. Pain 2005;118:170-5 (Pubitemid 41566596)
42. Kamanli A, Kaya A, Ardicoglu O, Ozgocmen S, Zengin FO, Bayik Y. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int 2005;25:604-11 (Pubitemid 41414058)